Market forces, capacity constraints, and government policies have driven the bioprocess industry to evaluate new technologies in mAb production with goals to maximize manufacturing flexibility and efficiency while minimizing risk and product cost. Focus is needed on technologies offering the highest return on investment based on ease-of-implementation, regulatory acceptance, and COGs reduction.
March 12, 2019 | 10:00 - 11:30 AM
This panel discussion will focus on case studies and perspectives from industry experts on the implementation of Bioprocessing 4.0 today, remaining gaps and barriers to overcome while addressing the following topics:
Merrilee Whitney, Head of BioContinuum™ Platform for Next Generation Bioprocessing, MilliporeSigma
March 13, 2019 | 01:40 - 02:10 PM
All biologics production processes focus on preventing adventitious microorganisms from entering upstream processes. There are numerous technologies to minimize contamination risks but they are not all suitable for every process. We will discuss the strengths and limitations of these technologies and explain how they can be integrated with advances in testing into a holistic upstream biosafety strategy.
Craig Jackson, Senior Product Manager, Biosafety, Process Solutions, MilliporeSigma